Evidence record · ER-KISSPEPTIN-IVF-028
Can kisspeptin-54 trigger oocyte maturation in high-risk IVF?
Kisspeptin-54 triggers oocyte maturation in women at high risk of ovarian hyperstimulation syndrome during IVF
Kisspeptin-54 triggered oocyte maturation in phase 2 IVF studies involving women at high risk of ovarian hyperstimulation syndrome. This supports a narrow specialist-procedure claim under intensive monitoring. It does not establish self-treatment, use outside IVF, superiority to every authorised trigger or safety of an online peptide product.
Claim boundary
What this verdict covers
The supported claim is limited to specialist IVF protocols in carefully selected high-risk women, with ultrasound, laboratory and clinical monitoring. It is not a general fertility-enhancement claim.
- Compound
- Kisspeptin-54
- Population
- Women at high risk of ovarian hyperstimulation syndrome in specialist IVF care
- Outcome
- Mature oocytes and embryo outcomes
- Record ID
- ER-KISSPEPTIN-IVF-028
Evidence synthesis
What the research can support
Phase 2 studies, including randomised work, reported mature oocytes and reproductive outcomes after kisspeptin-54 triggering in high-risk women. The programme is clinically relevant but smaller and more specialised than a broad authorisation package.
Why the confidence is moderate
Results depend on protocol, population and embryology setting. Rare adverse outcomes and comparative effectiveness need larger confirmatory studies.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-KISSPEPTIN-IVF-028 addresses one bounded question: Can kisspeptin-54 trigger oocyte maturation in high-risk IVF?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Kisspeptin-54 IVF phase 2 study | The study reported successful oocyte maturation in women at high risk of OHSS. | It does not support unsupervised or general fertility use. | 10 August 2026 |
| Randomised kisspeptin-54 IVF study | The trial adds controlled human evidence for a specialist trigger protocol. | It does not establish broad authorisation or every comparative claim. | 10 August 2026 |
| MHRA products database | The database provides current UK marketing-authorisation status. | A clinical trial does not itself create an authorisation. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Kisspeptin-54 for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Phase 2 studies, including randomised work, reported mature oocytes and reproductive outcomes after kisspeptin-54 triggering in high-risk women. The programme is clinically relevant but smaller and more specialised than a broad authorisation package. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Kisspeptin-54 authorised in the UK for this use?
Kisspeptin-54 remains a specialist investigational intervention rather than a generally authorised UK IVF trigger medicine. The studies do not support unsupervised use. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
Larger multicentre comparisons with authorised trigger strategies, live-birth outcomes, prespecified OHSS endpoints and regulatory assessment. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation